A multicenter trial of oxcarbazepine oral suspension monotherapy in children newly diagnosed with partial seizures: A clinical and cognitive evaluation |
| |
Authors: | So-Hee Eun Heung Dong Kim Hee Jung Chung Hoon-Chul Kang Joon Soo Lee Joon Sik Kim Su Jeong You Han Ku Moon Young-Mock Lee Dong Wook Kim Eun Sook Suh Ji Yeon Kim Juneyoung Lee Baik-Lin Eun |
| |
Institution: | 1. Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea;2. Department of Pediatrics, Pediatric Epilepsy Clinics, Severance Children''s Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea;3. Department of Pediatrics, National Health Insurance Corporation, Ilsan Hospital, Goyang, Republic of Korea;4. Department of Pediatrics, Keimyung University College of Medicine, Daegu, Republic of Korea;5. Department of Pediatrics, Epilepsy Center, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea;6. Department of Pediatrics, Yeungnam University College of Medicine, Daegu, Republic of Korea;7. Department of Pediatrics, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea;8. Department of Pediatrics, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;9. Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea |
| |
Abstract: | PurposeWe conducted a prospective, multicenter, open label trial to evaluate the effectiveness of oxcarbazepine (OXC) oral suspension as monotherapy for children newly diagnosed with partial seizures.MethodsThis trial included a two- to eight-week titration and stabilization period to achieve effective target doses and a 24-week maintenance phase. The primary outcome measure was the seizure-free rate over six months, while a secondary measure was the change in cognition and behavior from screening to the end of the maintenance phase. The effectiveness of OXC was compared in intellectually normal versus intellectually impaired children (intelligence quotient <70).ResultsWe enrolled 171 patients and analyzed 168 as the per-protocol (PP) group (3 patients had protocol violations). The mean age of the PP group was 8.4 ± 2.7 years. The maintenance dose of OXC was 24.9 ± 8.0 mg/kg/day. Of the 168 patients included in the efficacy analysis, 122 (72.6%) completed the study and 94 (56.0%) became seizure-free after the OXC treatment. Comparing the efficacy of OXC for intellectually normal and intellectually impaired patients, 79 (56.8%) of the 139 intellectually normal patients and 15 (51.7%) of the 29 intellectually impaired patients became seizure-free (P = 0.61). After treatment, intelligence scale scores improved in intellectually normal patients compared to the intellectually impaired children (P < 0.05). Social problems quantified by behavior scales improved in intellectually impaired patients compared to intellectually normal children (P < 0.05).ConclusionsOXC is effective and well-tolerated as monotherapy in children with partial seizures. There was no difference in the effectiveness of OXC between intellectually normal and intellectually impaired children. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|